Literature DB >> 32448985

Early left atrial dysfunction in idiopathic pulmonary fibrosis patients without chronic right heart failure.

Andrea Sonaglioni1, Antonella Caminati2, Roberto Lipsi3, Gian Luigi Nicolosi4, Michele Lombardo1, Claudio Anzà5, Sergio Harari3,6.   

Abstract

No data are actually available regarding the left atrial (LA) functional assessment by two-dimensional speckle tracking echocardiography (2D-STE) in early-stage idiopathic pulmonary fibrosis (IPF). The primary end-point of our study was to assess whether global LA peak strain (GLAPS), measured by 2D-STE analysis, may detect early alterations in LA function in IPF patients without right heart failure (RHF). Between September 2017 and January 2019, 50 consecutive IPF patients (73.8 ± 6.8 years, 36 males) without chronic RHF and 30 controls matched by age, sex and cardiovascular risk factors, were enrolled in an observational retrospective case-control study. All patients underwent a complete echocardiographic study implemented with 2D-STE analysis. GLAPS, left ventricular (LV) global longitudinal strain (GLS), right atrial (RA) reservoir strain (GSA+) and right ventricular (RV)-GLS were obtained in each patient. LVFP were significantly increased in IPF patients in comparison to controls (average E/e' ratio 14.4 ± 3.0 vs 9.6 ± 1.5, p < 0.0001), while LV-GLS was slightly reduced in IPF patients compared to controls (19.4 ± 3.6% vs 21.0 ± 2.2%, p = 0.03).Moreover, GLAPS was significantly impaired in IPF patients in comparison to controls (18.4 ± 3.7% vs 28.4 ± 5.6%, p < 0.0001).Finally, the two groups of patients did not show any statistically significant difference in both RA-GSA + (23.9 ± 3.7% vs 24.5 ± 4.0%, p = 0.49) and RV-GLS (- 22.6 ± 3.3% vs - 23.5 ± 3.0%, p = 0.22). Notably, LV-GLS was strongly inversely correlated both with RV/LV basal diameter ratio and TRV in IPF patients (r = - 0.87 and - 0.82, respectively) but not in controls (r = - 0.29 and - 0.27, respectively). This finding highlights a likely process of ventricular interdependence in non-advanced IPF, with consequent LV diastolic dysfunction and secondary impairment in LV-GLS and GLAPS. Early LA reservoir dysfunction in IPF patients may be secondary to LV diastolic dysfunction induced by ventricular interdependence and may develop before RV diastolic and systolic dysfunction.

Entities:  

Keywords:  Global left atrial peak strain; Idiopathic pulmonary fibrosis; Prognostic risk stratification

Year:  2020        PMID: 32448985     DOI: 10.1007/s10554-020-01887-5

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  4 in total

1.  Modified Haller index validation and correlation with left ventricular strain in a cohort of subjects with obesity and without overt heart disease.

Authors:  Andrea Sonaglioni; Gian Luigi Nicolosi; Roberta Trevisan; Alberto Granato; Maurizio Zompatori; Michele Lombardo
Journal:  Intern Emerg Med       Date:  2022-06-26       Impact factor: 5.472

2.  Mechanical concordance between left atrium and left atrial appendage in nonvalvular atrial fibrillation: can it be exploited to avoid transesophageal echocardiography prior to electrical cardioversion during Covid-19 pandemic?

Authors:  Andrea Sonaglioni; Michele Lombardo; Gian Luigi Nicolosi; Gian Franco Gensini; Giuseppe Ambrosio
Journal:  Int J Cardiovasc Imaging       Date:  2021-09-18       Impact factor: 2.316

3.  Incremental prognostic value of arterial elastance in mild-to-moderate idiopathic pulmonary fibrosis.

Authors:  Andrea Sonaglioni; Antonella Caminati; Gian Luigi Nicolosi; Michele Lombardo; Sergio Harari
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-01       Impact factor: 2.357

4.  Incremental diagnostic role of left atrial strain analysis in thrombotic risk assessment of nonvalvular atrial fibrillation patients planned for electrical cardioversion.

Authors:  Andrea Sonaglioni; Michele Lombardo; Gian Luigi Nicolosi; Elisabetta Rigamonti; Claudio Anzà
Journal:  Int J Cardiovasc Imaging       Date:  2021-01-03       Impact factor: 2.357

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.